Most Recent
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.
The Full Court has found an employee of e-commerce merchandise importer New Aim breached his duty of confidence by providing contact details of the company's suppliers, stored on WeChat on his personal phone, to a competitor.
Melbourne-based biopharma Telix has filed a lawsuit against Purdue Research Foundation seeking to invalidate its patent for blockbuster prostate cancer treatment Pluvicto.
Bayer and Teva have lost their challenge to Indian drug maker Cipla’s extension of its patent for an allergy medication, with IP Australia finding a failure to pay renewal fees on time was due to a genuine error.
AstraZeneca has won an interlocutory injunction barring Pharmacor from making a generic version of its blockbuster diabetes drug Forxiga while a patent case over the drug proceeds.
Aristocrat has fended off the Commissioner of Patents' challenge to a finding that its Lightning Link poker machine is capable of being patented, with the High Court declining to weigh in on the patent for a second time.
Zoetis has been ordered to pay Scidera’s costs of defending an unsuccessful summary dismissal application on a lump sum basis in a dispute over a bovine gene patent, with a judge rejecting its “premature” bid for a set-off.
The High Court will not hear sports merchandise company Fanatics' trade mark fight with AFL apparel maker FanFirm, which Fanatics argued would provide guidance on the defence of honest concurrent use.